CVE:MDP Medexus Pharmaceuticals (MDP) Stock Price, News & Analysis C$7.75 -0.40 (-4.91%) (As of 06/16/2021) Add Compare Share Share Today's RangeC$7.70▼C$8.1450-Day RangeC$7.75▼C$7.7552-Week RangeC$2.80▼C$9.75Volume40,981 shsAverage Volume68,619 shsMarket CapitalizationC$148.54 millionP/E RatioN/ADividend YieldN/APrice TargetC$3.18 Stock AnalysisStock Analysis Get Medexus Pharmaceuticals alerts: Email Address Ad Unstoppable Prosperity“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.You can find out what they are by clicking here now. About Medexus Pharmaceuticals Stock (CVE:MDP)Medexus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada and the United States. The company's primary products are Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with Hemophilia B; and Rupall, which is indicated for the treatment of seasonal allergic rhinitis, perennial allergic rhinitis, and chronic spontaneous urticaria in patients 2 years of age and older. Its products portfolio also include Cuvposa, which is indicated for sialorrhea in patients aged 3-18 years with neurologic conditions, such as cerebral; Gliolan, an orally administered drug used for the visualization of various brain tumors; and Treosulfan, a conditioning agent used prior to stem cell transplantation. The company was formerly known as Pediapharm Inc. and changed its name to Medexus Pharmaceuticals Inc. in December 2018. Medexus Pharmaceuticals Inc. is based in Verdun, Canada.Read More MDP Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MDP Stock News HeadlinesMay 24, 2024 | investing.comMedexus Pharmaceuticals Inc (MDP)May 8, 2024 | finance.yahoo.comWith A Return On Equity Of 20%, Has Medexus Pharmaceuticals Inc.'s (TSE:MDP) Management Done Well?July 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.February 13, 2024 | au.finance.yahoo.comMedexus Pharmaceuticals Inc (P731.BE)February 10, 2024 | finance.yahoo.comMedexus Pharmaceuticals Inc. Just Reported A Surprise Loss: Here's What Analysts Think Will Happen NextJanuary 30, 2024 | finance.yahoo.comMedexus Schedules Third Fiscal Quarter 2024 Conference CallNovember 30, 2023 | finance.yahoo.comBoasting A 23% Return On Equity, Is Medexus Pharmaceuticals Inc. (TSE:MDP) A Top Quality Stock?November 8, 2023 | finance.yahoo.comMedexus Announces Strong Fiscal Q2 2024 Results, Including Quarterly Revenue of US$30.3 MillionJuly 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.November 1, 2023 | finance.yahoo.comMedexus Schedules Second Fiscal Quarter 2024 Conference CallOctober 16, 2023 | finance.yahoo.comCanadian Investment Regulatory Organization Trading Halt - MDP.DBOctober 11, 2023 | finance.yahoo.comMedexus Pharmaceuticals' (TSE:MDP) earnings growth rate lags the 131% return delivered to shareholdersOctober 6, 2023 | finance.yahoo.comMedexus Announces Closing of C$10 Million Bought-Deal Public OfferingSeptember 15, 2023 | finance.yahoo.comShareholders May Be More Conservative With Medexus Pharmaceuticals Inc.'s (TSE:MDP) CEO Compensation For NowAugust 31, 2023 | msn.comMedexus Pharmaceuticals (MEDXF) Price Target Increased by 16.36% to 3.18August 23, 2023 | theglobeandmail.comClosing Bell: Medexus Pharmaceuticals Inc up on Wednesday (MDP)August 19, 2023 | finance.yahoo.comHere's Why We Think Medexus Pharmaceuticals (TSE:MDP) Is Well Worth WatchingJuly 13, 2023 | markets.businessinsider.comMedexus Pharmaceuticals Inc (MDP) Gets a Buy Rating from Stifel NicolausSee More Headlines Receive MDP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Medexus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeCVE SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A Current SymbolCVE:MDP CUSIPN/A CIKN/A Webwww.medexus.com Phone514-762-2626FaxN/AEmployeesN/AYear FoundedN/APrice Target and Rating Average Stock Price TargetC$3.18 High Stock Price TargetC$4.00 Low Stock Price TargetC$2.35 Potential Upside/Downside-59.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E Ratio9.23 P/E Growth-2153Net IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio1,174.36 Current Ratio1.19 Quick Ratio0.74 Sales & Book Value Annual SalesC$108.29 million Price / Sales1.37 Cash FlowC$0.62 per share Price / Cash Flow12.46 Book ValueC$0.38 per share Price / Book20.50Miscellaneous Outstanding Shares19,167,000Free FloatN/AMarket CapC$148.54 million OptionableNot Optionable BetaN/A A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for August 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Kenneth d'EntremontCEO & DirectorMr. Roland BoivinChief Financial OfficerMr. Bill PoncySr. VP of Commercial Operations - United StatesMr. Brian PetersVP of Sales & Marketing - United StatesMs. Tina Byers CFAExec. of Investor RelationsMr. Michael PineSr. VP of Bus. Devel. & StrategyMr. Michael David Adelman (Age 50)Gen. Mang., U.S. Operations More ExecutivesKey CompetitorsKnight TherapeuticsTSE:GUDAurora CannabisTSE:ACBSupreme CannabisTSE:FIREESSA PharmaCVE:EPIOrganigramTSE:OGIView All CompetitorsInsidersKenneth D'entremontBought 5,000 shares on 6/28/2024Total: C$9,000.00 ($1.80/share)Benoit GravelBought 3,200 shares on 2/13/2024Total: C$5,408.00 ($1.69/share) MDP Stock Analysis - Frequently Asked Questions How have MDP shares performed this year? Medexus Pharmaceuticals' stock was trading at C$7.75 at the beginning of the year. Since then, MDP shares have increased by 0.0% and is now trading at C$7.75. View the best growth stocks for 2024 here. How do I buy shares of Medexus Pharmaceuticals? Shares of MDP stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.Compare Top Brokerages Here. What other stocks do shareholders of Medexus Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Medexus Pharmaceuticals investors own include Gatekeeper Systems (GSI), Enghouse Systems (ENGH), Ag Growth International (AFN). This page (CVE:MDP) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Medexus Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Medexus Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.